^
    Back
    Association details:
    Biomarker:IGH mutation
    Cancer:Chronic Lymphocytic Leukemia
    Regimen: (cyclophosphamide + fludarabine IV + Rituxan (rituximab))
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    The panel emphasizes that FCR is the preferred first-line therapy option for IGHV-mutated CLL in patients <65 years without significant comorbidities.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Br J Haematol
    Title:

    Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group

    Published date:
    02/22/2021
    Excerpt:
    The median progression-free survival was 29 months, but was markedly longer in patients with mutated IGHV (median 53 months)...Low-dose FCR is a well-tolerated and effective first-line regimen for selected elderly/comorbid patients with CLL/SLL with favourable biology.
    DOI:
    10.1111/bjh.17373
    Trial ID:
    Q-lite